You just read:

NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

News provided by

NeuroSigma, Inc.

Apr 01, 2014, 07:00 ET